By Dennis Thompson HealthDay ReporterMONDAY, July 7, 2025 (HealthDay News) — Radiation therapy to treat cancer might be a ...

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

This newly launched program can save lives, with the proportion of cases identified at an early stage expected to rise from ...

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer ...

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with ...

More cancer is being spotted sooner in a screening programme which has “flipped” statistics for patients’, NHS bosses were told.

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...